United Therapeutics (UTHR) Tax Provisions (2009 - 2026)

United Therapeutics has disclosed Tax Provisions across 18 years of filings, most recently posting $43.4 million for Q1 2026.

• Tax Provisions for Q1 2026 came in at $43.4 million, down 57.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $321.3 million (down 9.03% YoY), and the FY2025 annual result was $379.2 million, up 10.26% from the prior year.
• Tax Provisions came in at $43.4 million for Q1 2026 at United Therapeutics, down from $79.7 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $101.3 million in Q1 2025 to a low of $34.6 million in Q2 2022.
• The 5-year median for Tax Provisions is $78.3 million (2023), against an average of $75.3 million.
• Across the five-year window, Tax Provisions surged 1538.1% in 2022 and slumped 57.16% in 2026, its largest moves.
• United Therapeutics' Tax Provisions stood at $46.7 million in 2022, then jumped by 67.67% to $78.3 million in 2023, then climbed by 21.58% to $95.2 million in 2024, then decreased by 16.28% to $79.7 million in 2025, then tumbled by 45.55% to $43.4 million in 2026.
• The last three Tax Provisions figures came in at $43.4 million (Q1 2026), $79.7 million (Q4 2025), and $99.3 million (Q3 2025), per Business Quant data.